Crossmark

Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab

Published Online: 2025-01-26

Authors

Li, Ziping https://orcid.org/0000-0003-0341-6098
Zhang, Fujing

Jin, Xianghong

Zhuang, Junling
Funding

Funding for this research was provided by:

Capital’s Funds for Health Improvement and Research (2022-2-4013)

National High Level Hospital Clinical Research Funding (2022-PUMCH-B-048)
License Information

Text and Data Mining valid from 2025-01-26

Version of Record valid from 2025-01-26
More Information

Article History

Received: 20 November 2024

Accepted: 15 January 2025

First Online: 26 January 2025

Declarations

:

: This study was approved by the Institutional Medical Ethics Committee (No. I-23PJ229) at Peking Union Medical College Hospital.

: Not applicable.

: All authors declare that they have no competing interest.

Document is current